Sign in
TerminatedEarly phase 1

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Key facts

Who runs it
Base Therapeutics (Shanghai) Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Early phase 1
People taking part
2 people enrolled
Started
1 Jul 2024
Ended
1 Jun 2025
Type of study
Interventional, 3 groups
Treatments tested
  • NK520
Record updated
30 September 2026
Why it stopped
poor accrual

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Participants must be between 18 and 75 years
  • Diagnostic Criteria:; Meet the 2016 World Health Organization (WHO) diagnostic criteria for acute myelocytic leukemia (AML), unsuitable for current treatments or patients with relapsed/refractory AML after ≥2 lines of therapy. The definition of relapsed/refractory acute myeloid leukemia is based on the 2017 Chinese Guidelines for Diagnosis and Treatment:; Relapsed AML: Diagnosis is confirmed when leukemia cells reappear in the peripheral blood or bone marrow blast cells exceed 5% after complete remission (CR) (excluding reasons such as bone marrow regeneration post-consolidation chemotherapy) or there is extramedullary infiltration by leukemia cells; Refractory AML: Initial cases unresponsive after two cycles of standard regimen treatment; recurrence within 12 months after CR and consolidation therapy; recurrence beyond 12 months with ineffectiveness of conventional chemotherapy; those who have relapsed twice or more; or persistent extramedullary leukemia
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • Expected survival of at least 12 weeks
  • Normal Organ Function

Who cannot take part

  • Severe bleeding tendency or coagulation disorders, or currently receiving thrombolytic therapy
  • Active tuberculosis (TB), currently undergoing anti-TB treatment, or treated for TB within 1 year prior to the study
  • Use of immunosuppressive drugs within 1 week before the first dose, excluding topical, inhaled, or other locally administered glucocorticoids, or physiologic doses of systemic glucocorticoids (not exceeding 10 mg/day prednisone equivalent) for allergic reactions or for managing respiratory distress from asthma, chronic obstructive pulmonary disease (COPD), etc
  • Receipt of live attenuated vaccines within 2 weeks before the first dose or planned during the study
  • Participation in another clinical trial and receipt of investigational drug within 4 weeks prior to the first dose
  • Receipt of immune-modulating drugs (including thymosin, interferons, except for local use to control pleural or ascitic fluid) within 2 weeks prior to the first dose
  • Human immunodeficiency virus (HIV)-infected individuals, or known active syphilis infection
  • Any other condition or situation in which the investigator deems the patient unsuitable for participation in this study
  • At screening, hepatitis B or C viral tests positive according to either:; Hepatitis B surface antigen (HBsAg) positive with serum hepatitis B virus- deoxyribonucleic acid (HBV-DNA) titer ≥1×10\^3 copies/mL or above normal limits; Hepatitis C virus (HCV) antibody positive
  • Acute promyelocytic leukemia

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

The 3 groups in the trial

  • Group A(low-dose group)Treatment being tested

    NK520: 3×10\^7NK/kg

    Treatment: NK520

  • Group B(medium-dose group)Treatment being tested

    NK520: 6×10\^7NK/kg

    Treatment: NK520

  • Group C(high-dose group)Treatment being tested

    NK520: 9×10\^7NK/kg

    Treatment: NK520

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK520 for Patients With Relapsed/Refractory Acute Myeloid Leukemia
Record updated
30 September 2026